AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02885948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, ineffective control arm
Trial: NCT05986292
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT05986292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV
Trial: NCT01017458
Drug: MK0773
DrugBank: MK-0773 (DB16244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 25mg oral tablets MK0773 bid, for 12 weeks
Trial: NCT01017458
Drug: Comparator: testosterone enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
Trial: NCT01017458
Drug: Comparator: placebo oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablet bid, for 12 weeks
Trial: NCT01017458
Drug: Comparator: placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intramuscular injection q14d, for 12 weeks
Trial: NCT02301910
Drug: Recombinant staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Trial: NCT03764488
Drug: 99mTc-MAG3-BIIB067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01171664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, one BID
Trial: NCT04119739
Drug: Ibuprofen Arginine
RxNorm normalized name: ibuprofen arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01171664
Drug: STAHIST
RxNorm normalized name: Stahist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAHIST in tablet form dosed one BID
Trial: NCT02686021
Drug: Metamizole and Ibuprofen
RxNorm normalized name: hydrocodone and ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Trial: NCT02686021
Drug: Ibuprofen and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Trial: NCT02845882
Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
Trial: NCT02845882
Drug: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
Trial: NCT02845882
Drug: Methotrexate, 6-mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
Trial: NCT03758989
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Trial: NCT03758989
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Trial: NCT02811055
Drug: Administration of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo once per day during 14 days
Trial: NCT02869295
Drug: NKTR-214
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
Trial: NCT00207714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
Trial: NCT04123795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use
Trial: NCT00812344
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, dosing through the Loc-I-Gut catheter, single dose
Trial: NCT01057901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the matched placebo which will be administered two tablets daily at bedtime.
Trial: NCT01036061
Drug: GSK618334 PET subjects
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET subjects
Trial: NCT01036061
Drug: GSK618334 Medium Dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Dose
Trial: NCT00803946
Drug: Ibuprofen Tablets, 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03825471
Drug: Opioid Anesthetics
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: consumption of opioids during general anesthesia
Trial: NCT03503708
Drug: Livitol-70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
Trial: NCT00005036
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005036
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00314249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral administration, twice daily for 12 weeks
Trial: NCT02129660
Drug: Dose 1 of glycopyrrolate, 2.0% QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 of glycopyrrolate Topical Wipes
Trial: NCT02129660
Drug: Dose 2 of glycopyrrolate, 3.0% QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2 of glycopyrrolate Topical Wipes
Trial: NCT01092299
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER Fast, 90mg, p.o. capsule
Trial: NCT01092299
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER Moderate, 90mg, p.o. capsule
Trial: NCT01092299
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER Slow, 90mg, p.o. capsule
Trial: NCT01092299
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR
Trial: NCT01092299
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR, 90 mg p.o. capsule
Trial: NCT02503345
Drug: ALLN-177 mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
Trial: NCT01092299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR
Trial: NCT01092299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER/MR
Trial: NCT02503345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
Trial: NCT02345928
Drug: Part 1: CNTO 7160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
Trial: NCT03245229
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet for oral administration
Trial: NCT00630682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 weeks of placebo 60mg capsules QD.
Trial: NCT00745615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
Trial: NCT01918111
Drug: adenosine infusion treatment
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continue hypertensive medication
Trial: NCT04582097
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same odor, color and size as the drug but without the active ingredient
Trial: NCT03970720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg matching placebo capsules four times a day
Trial: NCT03011463
Drug: oral administration of 500 mg clarithromycin
RxNorm normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of 500 mg clarithromycin with 240 ml tap water
Trial: NCT04485286
Drug: [68Ga]CBP8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
Trial: NCT00543790
Drug: PRA-027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
Trial: NCT01131728
Drug: Naproxen Sodium & Pseudoephedrine HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Trial: NCT01967888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic solution administered at 0.25 mL/kg/hour
Trial: NCT00183469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
Trial: NCT00965913
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
Trial: NCT02366065
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
Trial: NCT04540120
Drug: placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard opaque capsules containing 0 mg of API.
Trial: NCT02577042
Drug: PI-based regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
Trial: NCT01347879
Drug: Visonac PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream application prior to illumination with red light
Trial: NCT01347879
Drug: Vehicle cream with PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/vehicle cream application prior to illumination with red light
Trial: NCT01965535
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Trial: NCT00970931
Drug: Chlorthalidone plus amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
Trial: NCT00970931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo once a day, for 18 months
Trial: NCT01493531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Placebo QD
Trial: NCT01303874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN-matching placebo SC injections once weekly and MTX orally once weekly.
Trial: NCT01807962
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo = 5ml of sterile saline solution
Trial: NCT03854227
Drug: PF-06939999 dose escalation
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06939999 orally at escalating doses on a continuous basis
Trial: NCT03640468
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive normal saline 10 mL
Trial: NCT01554969
Drug: capecitabine + ganetespib
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily.
Trial: NCT04169386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose administered subcutaneously
Trial: NCT01027884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
Trial: NCT00782327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo capsule
Trial: NCT03670043
Drug: Psyllium powder
RxNorm normalized name: psyllium Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate whether Psyllium will alleviate diarrhea
Trial: NCT00844727
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00844727
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT02907554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group receives a placebo
Trial: NCT04438629
Drug: COVID-19 treatment
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
Trial: NCT03936959
Drug: LY3434172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00701935
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, twice a day
Trial: NCT01486485
Drug: heparinized saline priming group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01486485
Drug: nafamostat infusion after heparinized saline priming
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539317
Drug: Topical saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline applied to the vestibule mucosa will not reverse the local tenderness
Trial: NCT00553865
Drug: OJP-2028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Trial: NCT01328171
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Trial: NCT00021320
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01236105
Drug: LY2624803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (po), once.
Trial: NCT01668927
Drug: Proton Pump Inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668927
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02250027
Drug: HL301 300mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules at once, 3 times a day, for 7 days
Trial: NCT02250027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules at once, 3 times a day, for 7 days
Trial: NCT04623385
Drug: The standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infected patients will receive the standard therapy for COVID-19 for 14 days
Trial: NCT02217345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
Trial: NCT02857725
Drug: BAY 987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Trial: NCT01068925
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days
Trial: NCT00800683
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching BI 1356 taken once daily
Trial: NCT02857725
Drug: SPF 15 Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Trial: NCT03965078
Drug: topical (eye drop) anti-inflammatories
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
Trial: NCT00457873
Drug: 0.9% saline in 5% dextrose (intravenous)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01318252
Drug: AL-54478 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02615730
Drug: GSK2636771
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
Trial: NCT04411524
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week
Trial: NCT00475852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Trial: NCT02065791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally (by mouth) once daily
Trial: NCT02449720
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal instillation and infusion
Trial: NCT03759288
Drug: Humira®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
Trial: NCT03759288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Trial: NCT03010761
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - Cap
Trial: NCT03280095
Drug: co-codamol 30mg/500mg tablet
RxNorm normalized name: Co-Gesic 5 MG / 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02713243
Drug: LJN452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing LJN452
Trial: NCT00447018
Drug: 7.45% hypertonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01335464
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching BIBF1120, BID
Trial: NCT01335464
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF1120 BID (twice daily)
Trial: NCT03582293
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule two times a day for a total of 28 days
Trial: NCT02677805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
Trial: NCT02535000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02175407
Drug: ASP1707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral